Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1994 Nov 8;91(23):10873-7.
doi: 10.1073/pnas.91.23.10873.

Serum Vpr regulates productive infection and latency of human immunodeficiency virus type 1

Affiliations

Serum Vpr regulates productive infection and latency of human immunodeficiency virus type 1

D N Levy et al. Proc Natl Acad Sci U S A. .

Abstract

In human immunodeficiency virus (HIV)-positive individuals, the vast majority of infected peripheral blood cells and lymph node cells may be latently or nonproductively infected. The vpr open reading frame of HIV-1 encodes a 15-kDa virion-associated protein, Vpr. The vpr gene has been shown to increase virus replication in T cells and monocyte/macrophages in vitro. We have previously reported that vpr expression in various tumor lines leads to growth inhibition and differentiation, indicating that Vpr may function as a regulator of cellular permissiveness to HIV replication. Here we show that Vpr protein is present in significant amounts in the serum of AIDS patients. Purified serum Vpr activated virus expression from five latently infected cell lines, U1, OM.10.1, ACH-2, J1.1, and LL58. Serum Vpr also activated virus expression from resting peripheral blood mononuclear cells of HIV-infected individuals. Together, these findings implicate serum Vpr in the activation of HIV replication in vivo and in the control of latency. Anti-Vpr antibodies inhibited Vpr activity, suggesting that humoral immunity modulates Vpr activity in vivo. These results have broad implications for the virus life cycle and for the prospective control of HIV replication and pathogenesis.

PubMed Disclaimer

References

    1. J Acquir Immune Defic Syndr. 1990;3(2):115-22 - PubMed
    1. J Acquir Immune Defic Syndr. 1990;3(1):11-8 - PubMed
    1. J Virol. 1990 Feb;64(2):864-72 - PubMed
    1. J Virol. 1990 Jun;64(6):3097-9 - PubMed
    1. J Exp Med. 1990 Jul 1;172(1):151-8 - PubMed

Publication types

MeSH terms

Substances